Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNMT | Q14749 | 3/20 | 0.80 |
| ▸ | AHCY | P23526 | 4/20 | 0.72 |
| ▸ | NADK | O95544 | 1/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.71 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.71 |
| ▸ | PNMT | P11086 | 1/20 | 0.71 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.71 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.70 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9550942 | 1.00 | GNMT (0.80) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL17551942 | 1.00 | GNMT (0.80) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL19434095 | 1.00 | GNMT (0.80) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL6897965 | 0.91 | DOT1L (0.76) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL7054700 | 0.90 | GNMT (0.74) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL6907266 | 0.90 | GNMT (0.74) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL6902821 | 0.90 | GNMT (0.74) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL7054701 | 0.90 | GNMT (0.74) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL6900840 | 0.89 | GNMT (0.77) | GNMTAHCYNADKDOT1LDNMT3B | |
| SCHEMBL6899844 | 0.89 | GNMT (0.77) | GNMTAHCYNADKDOT1LDNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |
| JP-5208993-A | — | — | None | — | — | JP | disclosed |
| US-10183965-B2 | Cofactor analogues for methyltransferases | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2019-01-22 | — | — | US | disclosed |
| US-20170283453-A1 | COFACTOR ANALOGUES FOR METHYLTRANSFERASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-10-05 | — | — | US | disclosed |
| EP-3186266-A1 | S-ADENOSYL-L-CYSTEINE ANALOGUES AS COFACTORS FOR METHYLTRANSFERASES | Katholieke Universiteit Leuven (BE) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030546-A1 | S-ADENOSYL-L-CYSTEINE ANALOGUES AS COFACTORS FOR METHYLTRANSFERASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-03-03 | — | — | WO | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| JP-H05208993-A | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ISCHEMIA | BIORESEARCH SPA | 1993-08-20 | — | — | JP | disclosed |
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183965-B2 | Cofactor analogues for methyltransferases | BHMT, BHMT2, NNMT | GNMT 21/4885AHCY 10/4885NADK 163/4885 |
| US-20170283453-A1 | COFACTOR ANALOGUES FOR METHYLTRANSFERASES | BHMT, BHMT2, NNMT | GNMT 21/4885AHCY 10/4885NADK 163/4885 |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | GNMT 12/4885AHCY 62/4885NADK 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.